ArticleNeurology. Clinical practice2021
Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease: An Updated Clinicopathologic Study.
Article in Neurology. Clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 43 citations in OpenAlex.
- Diffusion MRI and α-Synuclein Seed Amplification Status in Parkinson's Disease.Annals of neurology · 2026Article
- Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".Annals of neurology · 2026Article
- Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.JAMA neurology · 2026Article
- Case report of Parkinson's disease in isolated congenital anosmia with absent olfactory bulbs.NPJ Parkinson's disease · 2026Article
- Machine learning classification of early-stage Parkinson's disease using sit-to-walk biomechanical features.Scientific reports · 2026Article
- Pathology and genetics in a global cohort of Parkinsonian Disorders.medRxiv : the preprint server for health sciences · 2026Article
- Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders.International journal of environmental research and public health · 2026Review
- Parkinson's Disease: From Gene-Environment Risk to Precision Therapy.Medical sciences (Basel, Switzerland) · 2026Review
- Clinical utility of skin biopsy detection of phosphorylated alpha-synuclein in an outpatient practice.Frontiers in neurology · 2026Article
- A data-driven SSM/PCA analysis approach for differential diagnosis of parkinsonism usingNeuroImage. Clinical · 2026Article
- Automated eye-tracking for Parkinson's disease diagnosis: a proof-of-concept cascade classifier study.Clinical parkinsonism & related disorders · 2026Article
- Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases.NPJ Parkinson's disease · 2025Article
- Post-Acute COVID-19 Effects on Diagnostic Conversion Rates And Standardized Cognitive and Motor Test Scores in a Longitudinal Study of Independent, Community-Recruited Elderly Subjects.medRxiv : the preprint server for health sciences · 2025Article
- The quest for Parkinson's disease biomarkers: traditional and emerging multi-omics approaches.Molecular biology reports · 2025Review
- Minimal Clinically Important Difference of Average Daily Steps Measured Through a Consumer Smartwatch in People With Mild-to-Moderate Parkinson Disease: Cross-Sectional Study.JMIR mHealth and uHealth · 2025Article
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Incidence of antiepileptic drug use in Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Article
- Toward a biological definition of neuronal and glial synucleinopathies.Nature medicine · 2025Review
- Predicting Post-Mortem α-Synuclein Pathology by the Combined Presence of Probable REM sleep behavior disorder and Hyposmia.Movement disorders clinical practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo update data for diagnostic accuracy of a clinical diagnosis of Parkinson disease (PD) using neuropathologic diagnosis as the gold standard.
methodsData from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) were used to determine the predictive value of a clinical PD diagnosis. Two clinical diagnostic confidence levels were used, possible PD (PossPD, never treated or not responsive) and probable PD (ProbPD, 2/3 cardinal clinical signs and responsive to dopaminergic medications). Neuropathologic diagnosis was the gold standard.
resultsBased on the first visit to AZSAND, 15/54 (27.8%) PossPD participants and 138/163 (84.7%) ProbPD participants had confirmed PD. PD was confirmed in 24/34 (70.6%) ProbPD with <5 years and 114/128 (89.1%) with ≥5 years disease duration. Using the consensus final clinical diagnosis following death, 161/187 (86.1%) ProbPD had neuropathologically confirmed PD. Diagnostic accuracy for ProbPD improved if included motor fluctuations, dyskinesias, and hyposmia, and hyposmia for PossPD.
conclusionsThis updated study confirmed lower clinical diagnostic accuracy for elderly, untreated or poorly responsive PossPD participants and for ProbPD with <5 years of disease duration, even when medication responsive. Caution continues to be needed when interpreting clinical studies of PD, especially studies of early disease, that do not have autopsy confirmation. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that a clinical diagnosis of ProbPD at the first visit identifies participants who will have pathologically confirmed PD with a sensitivity of 82.6% and a specificity of 86.0%.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.